United States
#00280
Implements
#00378 Expand vaccines that prevent infections and antibiotic demand
Implementer
United States immunization programmes, healthcare providers and public-health agencies
Location
Description
The United States introduced pneumococcal conjugate vaccination (PCV7, later expanded to PCV13) for children in 2000. Vaccination reduced invasive pneumococcal disease caused by vaccine serotypes — many of which were antibiotic-resistant — in vaccinated children and through herd protection in unvaccinated adults. Replicating programmes should account for serotype replacement: non-vaccine serotypes can expand to partially offset gains, requiring ongoing surveillance and periodic updates to vaccine valency.
Metrics
2Lessons learned
- Vaccines targeting antibiotic-resistant serotypes reduce resistant disease burden and lower antibiotic demand without requiring pathogen-level diagnosis for each prevented infection — a scalable advantage over treatment-based approaches.
- Serotype replacement is a documented post-introduction phenomenon; sustained surveillance infrastructure and willingness to update vaccine composition are prerequisites for maintaining programme effectiveness.
Sources
2